Berberine for Alzheimer's Disease
Also known as: Berberine HCl, Goldenseal extract
Berberine's AMPK activation and anti-inflammatory effects address the metabolic dysfunction and neuroinflammation in Alzheimer's.
Mechanism of Action
Berberine activates AMPK, promoting autophagy and amyloid clearance. It inhibits BACE1 (β-secretase), directly reducing amyloid-beta production. Anti-inflammatory effects (NF-κB suppression) reduce neuroinflammation. Gut microbiome modulation through the gut-brain axis may influence Alzheimer's progression.
General mechanism: Isoquinoline alkaloid. AMPK activator, NF-κB inhibitor, BACE1 inhibitor, gut microbiome modulator, telomerase inhibitor.
Current Evidence
Preclinical studies show reduced amyloid pathology and cognitive improvement in AD models. Human studies are limited. The gut-brain axis modulation angle is a growing area of interest.
Clinical Status: Preclinical for Alzheimer's. No clinical trials specific to AD.
Safety Profile
GI effects (diarrhea, constipation). Should not be combined with metformin (additive hypoglycemia risk). Contraindicated in pregnancy. Generally well-tolerated.
Key Research Questions
- Can berberine's BACE1 inhibition complement anti-amyloid antibodies?
- Does gut microbiome modulation influence Alzheimer's progression through the gut-brain axis?